Skip to main content
Menu
Main navigation
News
News sub-navigation
All news
Seminars
Presentation
Presentation sub-navigation
CREATIS
Organigram
People directory
Staff
Contacts
Access
Research
Research sub-navigation
Research teams
Transversal projects
Structuring projects
Imaging platform
Activity reports
Data information note
Contributions
Contributions sub-navigation
Publications
Patents
Software
Studies & Training
Studies & Training sub-navigation
Implications dans les formations
Doctoral Studies
Jobs Opportunities
French
English
Search
Search
Search
Search
Search
Search API form
Search
User account menu
Account
Log in
Breadcrumb
Accueil
Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Barre liens pratiques
Authentication
Intranet
Rss feed
Creatis on Twitter
Webmail
French
English